newsfilter
← Latest News
PR Newswire·

NeuroSense Provides Business Update and Progress for the First Half of 2026

Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company focused on developing disease-modifying ...